Alexey V. Danilov, MD, PhD, spoke with Blood Cancers Today about his 2022 SOHO Annual Meeting presentation, which addressed targeted and emerging therapies for CLL.
Alexey V. Danilov, MD, PhD, Talks About Novel Agents for CLL
By Leah Sherwood - Last Updated: February 1, 2023Post Tags:SOHO 2022
Related Posts
Dr. Ryan Jacobs reviews the latest CLL data, highlighting time-limited regimens, BTK combos, and clinical trial updates.
AMPLIFY trial shows AVO combo achieves deep remissions in CLL patients with high-risk TP53 aberrations.
10-year RESONATE-2 results show ibrutinib delivers lasting survival benefits for CLL/SLL as first-line therapy.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Dr. Sanam Loghavi outlines genetic testing, MRD monitoring, and evolving strategies in newly diagnosed CLL.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.